Your session is about to expire
← Back to Search
Pembrolizumab + Carboplatin for Recurrent Gynecologic Cancer
Study Summary
This trial is testing pembrolizumab + carboplatin to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 1301 Patients • NCT03038100Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood clotting time is normal or managed with medication.I haven't had cancer treatment in the last 2 weeks or have recovered from its side effects.I have stable brain metastases, not on steroids for 14 days, and no carcinomatous meningitis.I have not received a live vaccine within the last 30 days.I have ovarian, fallopian tube, or peritoneal cancer and have had chemotherapy including platinum-based treatment.My CA-125 levels have doubled after my recent cancer treatment.I have a history of early-stage ovarian cancer.My hemoglobin level is above 9 g/dL without needing transfusions or EPO recently.I am 18 years old or older.I have fluid buildup in my abdomen or around my lungs.I am currently being treated for an infection.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I haven't needed systemic treatment for an autoimmune disease in the last 2 years.I haven't had cancer treatment with a monoclonal antibody in the last 4 weeks or have recovered from its side effects.I have been treated with pembrolizumab before.I have been diagnosed with HIV.I have a serious heart condition.I am fully active or restricted in physically strenuous activity but can do light work.My kidney function, measured by creatinine levels, is within the acceptable range.I have had lung inflammation that needed steroids.My cancer cannot be measured by scans and I have no symptoms from fluid build-up.I have another cancer besides skin or in situ cervical cancer that needs treatment.My CA-125 levels returned to normal after my first cancer treatment.I have severe allergies to certain cancer drugs or uncontrolled asthma.My blood clotting time is normal or managed if I'm on blood thinners.
- Group 1: Treatment (carboplatin, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are involved in this medical experiment?
"Yes, clinicaltrials.gov reflects that this trial is actively enrolling subjects. It was initially published on March 18th 2021 and recently modified on September 7th 2022. There are 22 spots available at one location for prospective participants."
What conditions have been effectively managed by Carboplatin?
"As a form of chemotherapy, carboplatin has been proven to be effective in treating many forms of cancer. Aside from malignant neoplasms, it can also help manage unresectable melanoma, cases with microsatellite instability and those at high risk for recurrence."
To what degree does Carboplatin pose an adverse health risk?
"Since this is a Phase 2 trial, we can assume that there exists some evidence of Carboplatin's safety but none verifying its efficacy. We thus rate the medication as having an overall safety level of 2 on our scale from 1 to 3."
Are there any enrolment opportunities for this trial currently available?
"Clinicaltrials.gov suggests that this study is still seeking participants, with the original posting on March 18th 2021 and an update posted just last week (September 7th 2022)."
What other research has investigated the effects of Carboplatin?
"Presently, there are 1546 active clinical trials involving Carboplatin with 310 such studies in the third phase. Houston, Texas is leading these experiments; however, it should be noted that research for this drug is being conducted across 71991 locations worldwide."
Share this study with friends
Copy Link
Messenger